Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment
about
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryAnti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.Gold nanoparticles to improve HIV drug delivery.Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionAn Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.Investigational protease inhibitors as antiretroviral therapies.New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy.Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy.Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.
P2860
Q28081272-88614275-544A-4FE8-AF64-167056369193Q34869449-9DCACA18-A012-47C6-8C4F-0595347622C1Q35314702-ED0520A3-9B07-45FF-8F44-080C4319AF61Q35847982-0B397A96-19E0-443A-B5F8-094758B5D090Q36111190-EA873DA4-CDA4-4649-ACEB-115ACB525E7BQ36933427-5B97D989-8709-4627-A108-963841B902D2Q37071435-BA4D9164-FA50-42BA-AF05-71406AC8F111Q37538618-CD2F740D-A191-4E61-A3AC-1CBF8156C40BQ37582521-2E99471C-2D75-48CA-8F88-79D82B1914B7Q38198221-42BD9D04-B024-449D-9D59-456093AF985DQ38495022-2F0D179D-8AD8-4034-9059-90986B10BD49Q39243464-8A28A53A-35BB-4AB6-B13D-6F47A3ED3977Q40358789-6C47E9EF-4A3D-4BE3-AC5F-6DE0BE63BD1AQ55286937-9E9327BB-BEB3-4A6C-9D8F-C21B16F5A2E0Q55338133-6AA145B6-2686-4089-BC90-BFECB0209132
P2860
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Polymeric nanoparticles contai ...... drugs for HIV type 1 treatment
@en
type
label
Polymeric nanoparticles contai ...... drugs for HIV type 1 treatment
@en
prefLabel
Polymeric nanoparticles contai ...... drugs for HIV type 1 treatment
@en
P2093
P2860
P356
P1476
Polymeric nanoparticles contai ...... drugs for HIV type 1 treatment
@en
P2093
Annemarie Shibata
Bridget Sanford
Emily McMullen
Michael Belshan
Michael Goede
P2860
P304
P356
10.1089/AID.2012.0301
P577
2013-02-01T00:00:00Z